Quotes

Back To Menu

Nippon India Pharma Fund (G) Equity - Pharma
INVEST

Plan: OPEN | Option: Growth | Sailesh Raj Bhan

04 Dec 25 | 12:00 AM

516.93 2.48 (0.48%)

  • Underperforms

    -0.24%

    Return (1Y)

    underperformed BSE Healthcare TRI by -48.56%

  • More Volatile

    0.90%

    Standard Deviation (1Y)

    Higher Equity - Pharma by 0.90%

  • Inconsistent

    /0

    Months

    Has underperformed Equity - Pharma

  • Value research rating

    Not Rated

Stock Composition

NAV

Scheme Trivia

  • Reliance Pharma Fund (G) fund has been the 6th best in 5Y performance in the Equity - Pharma category

  • Reliance Pharma Fund (G) fund has been given the 6th best Risk adjusted performance for the past 5Y in the Equity - Pharma category

  • Reliance Pharma Fund (G) fund has been the 7th best in the 5Y SIP performance in the Equity - Pharma category

Critical Parameters

Everyone of us wants to create wealth by investing in top funds. Have a look at the key parameters that you need to check before deciding to invest in a mutual fund.

Returns

In last 1 year Nippon India Pharma Fund (G), has underperformed by -48.56% (CAGR difference)

-0.24%

Underperforms

This is Alpha

Performance Chart for Rs

Invested in

05 Dec 2024

Risk

In last 1 year , the volatility of Nippon India Pharma Fund (G) is Higher than by 0.90%

0.90%

More Volatile

Risk Meter

Peer Comparison on Risk - Return

Consistency

For out of Last 0 Months, i.e 0% of the times It underperformed its benchmark, Equity - Pharma

Consistency Meter

Outperforming Stocks Vs. Underperforming Stocks

Based on the last 1year analysis, currently there are, the benchmark the benchmark

View Stock Composition